United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

At the forefront of this movement is Andre Dowdell Jr., CEO and founder of Liquida Capital, an American-based financial services firm reshaping how businesses access and use capital ...

Yutrepia's maker, Liquidia, has scheduled a first commercial shipment of the PH therapy to be available at specialty ...

This decision came after the full FDA approval of YUTREPIA inhalation powder for adults with pulmonary arterial hypertension ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Shares of Liquidia Technologies Inc (NASDAQ: LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation ...

YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary ...

Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of $37.00. The company’s shares closed ...

In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $23.00. The compan ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation's LQDA Yutrepia (treprostinil) ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $27.5, a high estimate of $36.00 ...